Phathom Pharmaceuticals Announces FDA Approval of Voquezna (vonoprazan) Tablets for the Relief of Heartburn Associated with Non-Erosive GERD in Adults

July 18, 2024

Phathom Pharmaceuticals announces FDA approval of Voquezna (vonoprazan) tablets for treating heartburn associated with Non-Erosive GERD in adults, marking a significant milestone for millions of GERD patients.

Related Clinical Trials

A Study to Evaluate the Efficacy and Safety of Vonoprazan Compared to Placebo for Relief of Heartburn in Participants With Symptomatic Non-Erosive Gastroesophageal Reflux Disease (NERD)

Highlighted Terms

vonoprazan Takeda H. pylori infection Phathom Pharmaceuticals Erosive GERD amoxicillin clarithromycin U.S. Food and Drug Administration Erosive Esophagitis NCT05195528 Voquezna Non-Erosive GERD University of Tennessee College of Medicine

Related News

drugs.com

Phathom Pharmaceuticals Announces FDA Approval of Voquezna (vonoprazan) Tablets for the Relief of Heartburn Associated with Non-Erosive GERD in Adults